FibroBiologics, a clinical-stage biotechnology company, announced a registered direct offering and private placement.
The offering includes the issuance and sale of common stock shares at $0.335 per share.
The aggregate gross proceeds are expected to be approximately $1.5 million.
Offering Details
4,477,614 shares of common stock offered at $0.335 per share with unregistered warrants for additional proceeds.
Use of Proceeds
Intended for working capital and general corporate purposes.
Legal Compliance
Offering made under shelf registration statement on Form S-3 and private placement under Section 4(a)(2) of the Securities Act.
- The offering is expected to provide FibroBiologics with additional funding for its research and development activities.
- The successful completion of the offering demonstrates investor confidence in the company's future prospects.
The closing of the offering is expected to occur on November 25, 2025, subject to customary closing conditions. FibroBiologics aims to utilize the raised funds strategically to support its ongoing operations and growth initiatives.